Profile data is unavailable for this security.
About the company
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
- Revenue in USD (TTM)15.07m
- Net income in USD-81.22m
- Incorporated2008
- Employees107.00
- LocationCarisma Therapeutics Inc245 1st St Ste 1800CAMBRIDGE 02142-1292United StatesUSA
- Phone+1 (617) 444-8550
- Fax+1 (617) 858-0911
- Websitehttps://sesenbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ovid Therapeutics Inc | 473.53k | -50.68m | 53.33m | 40.00 | -- | 0.6797 | -- | 112.62 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Provectus Biopharmaceuticals Inc | 590.75k | -2.78m | 53.43m | 4.00 | -- | -- | -- | 90.44 | -0.0066 | -0.0066 | 0.0014 | -0.0178 | 0.4221 | -- | 1,358.05 | 147,687.50 | -198.50 | -276.33 | -- | -- | -- | -- | -470.31 | -1,667.76 | -- | -10.24 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
VolitionRX Ltd | 797.03k | -34.91m | 53.49m | 110.00 | -- | -- | -- | 67.11 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
Passage Bio Inc | 0.00 | -84.44m | 54.96m | 58.00 | -- | 0.5238 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -47.73 | -48.56 | -52.17 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
vTv Therapeutics Inc | 1.00m | -20.62m | 55.03m | 16.00 | -- | 2.65 | -- | 55.03 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
Enzo Biochem Inc | 33.34m | -17.55m | 55.06m | 179.00 | -- | 0.794 | -- | 1.65 | -0.3516 | 0.9194 | 0.6633 | 1.35 | 0.4028 | 1.66 | 4.91 | 186,257.00 | -21.20 | -12.21 | -34.50 | -15.79 | 43.66 | 37.09 | -52.63 | -18.76 | 3.16 | -- | 0.053 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
Cidara Therapeutics Inc | 46.38m | -36.47m | 55.47m | 69.00 | -- | -- | -- | 1.20 | -8.07 | -8.07 | 10.26 | -3.90 | 0.6899 | -- | 2.80 | 672,144.90 | -54.24 | -65.23 | -218.59 | -154.37 | 76.93 | -- | -78.63 | -100.61 | 0.6047 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
Carisma Therapeutics Inc | 15.07m | -81.22m | 57.74m | 107.00 | -- | 5.30 | -- | 3.83 | -2.01 | -2.01 | 0.3723 | 0.2623 | 0.1311 | -- | -- | 140,869.20 | -70.64 | -30.87 | -83.17 | -34.47 | -- | -- | -538.81 | -255.66 | -- | -- | 0.1717 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
Aileron Therapeutics Inc | 0.00 | -18.07m | 61.31m | 15.00 | -- | 1.07 | -- | -- | -3.19 | -3.19 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -31.05 | -65.99 | -33.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Personalis Inc | 74.15m | -92.61m | 61.81m | 223.00 | -- | 0.5067 | -- | 0.8336 | -1.89 | -1.89 | 1.51 | 2.35 | 0.3172 | 6.50 | 5.04 | 332,493.30 | -39.62 | -28.84 | -46.08 | -34.72 | 25.59 | 28.65 | -124.90 | -96.01 | 3.56 | -- | 0.0209 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 62.24m | 2.00 | -- | 12.48 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.60m | 3.84% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.56m | 3.76% |
University of Pennsylvania (Investment)as of 31 Mar 2024 | 1.25m | 3.01% |
Geode Capital Management LLCas of 31 Mar 2024 | 528.59k | 1.27% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 525.11k | 1.26% |
Renaissance Technologies LLCas of 31 Mar 2024 | 226.00k | 0.54% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 214.88k | 0.52% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 210.70k | 0.51% |
Teachers Advisors LLCas of 31 Mar 2024 | 86.47k | 0.21% |
BlackRock Investment Management LLCas of 31 Mar 2024 | 78.39k | 0.19% |